Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

HIV Cure – Just another fantasy?
2016-07-27

Description: HIV Cure – Just another fantasy? Tags: HIV Cure – Just another fantasy?

Dr Dominique Goedhals, Prof John Frater,
Dr Thabiso Mofokeng and Dr Jacob Jansen van Vuuren,
attended the lecture. Prof Frater has been working in
collaboration with the UFS Department of Internal
Medicine on HIV resistance and HIV immunology
since 2007.

Photo: Nonsindiso Qwabe

Twenty-years ago, after a person had been diagnosed with HIV, their lifespan did not exceed three years, but thanks to the success of antiretroviral therapy programmes, life expectancy has risen by an average of ten years. However, is antiretroviral therapy always going to be for life? This is the societal issue that Professor John Frater, addressed in his talk at the University of the Free State. He is an MRC Senior Clinical Fellow, Associate Professor and Honorary Consultant Physician in Infectious Diseases at  Oxford University.

Antiretroviral medicine therapeutic

The discovery of antiretroviral therapy - the use of HIV medicines to treat the virus - has had a positive effect on the health and well-being of people living with it, improving their quality of life. Unfortunately, if treatment is stopped, HIV rebounds to the detriment of the patient. Now, research has shown that some patients, who are treated soon after being infected by HIV, may go off treatment for prolonged periods. Work is being done to predict who will be able to stop treatment.

“The difference made by starting treatment earlier is enormous. Delaying treatment is denying yourself the right to health,” Professor Frater says. However, this does not mean that the virus is cured. “A person can live for ten years without being on HIV treatment, but is that enough?” he went on to ask.

Healthy lifestyles encouraged

The National Department of Health will adopt a test and treat immediately strategy later this year to improve patient health and curb the spread of HIV. ,This is another reason why everybody should know their status and start treatment as soon as possible.

Search for a cure continues

More research is being conducted to establish whether HIV can be eradicated. Remission gives hope that a permanent cure may be found eventually. “Will a cure for HIV ever be found? Time will tell,” he concluded.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept